NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
kenneth o byrne
AD Scientific Index 2024
Natural Sciences / Molecular Biology & Genetics
Queensland University of Technology - Brisbane / Australia
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
kenneth o byrne's MOST POPULAR ARTICLES
1-)
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancerM Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...N engl J med 375, 1823-1833, 201676272016
2-)
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung CancerJC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ...New England journal of medicine 378 (2), 113-125, 201839522018
3-)
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancerSJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...New England Journal of Medicine 377 (20), 1919-1929, 201740482017
4-)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung CancerAT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...New England Journal of Medicine 368 (25), 2385-2394, 201340552013
5-)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsLV Sequist, JCH Yang, N Yamamoto, K O\'Byrne, V Hirsh, T Mok, ...Journal of clinical oncology 31 (27), 3327-3334, 201337392013
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept